Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | iC9-CAR.B7-H3 T-cells |
Synonyms | |
Therapy Description |
iC9-CAR.B7-H3 T-cells are T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting B7-H3 (CD276) and an inducible caspase 9, which potentially induce killing of B7-H3 (CD276)-expressing tumor cells (Journal for ImmunoTherapy of Cancer 2023;11). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
iC9-CAR.B7-H3 T-cells | iC9-CAR.B7-H3 T cells | iC9-CAR.B7-H3 T-cells are T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting B7-H3 (CD276) and an inducible caspase 9, which potentially induce killing of B7-H3 (CD276)-expressing tumor cells (Journal for ImmunoTherapy of Cancer 2023;11). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06305299 | Phase I | Cyclophosphamide + Fludarabine iC9-CAR.B7-H3 T-cells | Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells | Recruiting | USA | 0 |
NCT06347068 | Phase I | iC9-CAR.B7-H3 T-cells Cyclophosphamide + Fludarabine | Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells | Recruiting | USA | 0 |
NCT06158139 | Phase I | iC9-CAR.B7-H3 T-cells | Autologous CAR-T Cells Targeting B7-H3 in PDAC | Recruiting | USA | 0 |